Composition and method for improving function of embryonic kidney transplants

• US 7,074,762 B2
• Filed: 12/29/1998
• Issued: 07/11/2006
• Est. Priority Date: 01/05/1998
• Status: Expired due to Fees

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Hammerman, Marc R., Rogers, Sharon A.
• Primary Examiner(s): Gupta, Anish
• Application Number:
  US09/222,460
• Publication Number:
  US 20030086909A1
• Time in Patent Office: 2,751 Days
• Field of Search: 514/12, 424/93.1, 424/93.21, 424/93.9, 435/375
• US Class Current: 604/892.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

A method and composition for enhancing the development of metanephric tissue upon transplantation into an allogenic or xenogenic host are disclosed. Metanephric tissue is removed from an embryonic donor and is contacted with a composition comprising one or more growth factors for metanephric development. The composition can be administered to the metanephric tissue in vitro prior to implantation of the donor tissue in the transplant recipient, or can be administered in vivo either during or subsequent to the transplantation procedure.

Claims

1. A method for the treatment of metanephric tissue for transplanted into a recipient comprising:

a. contacting said metanephric tissue, in vitro, with a growth factor-containing composition comprising vascular endothelial growth factor; and

b. transplanting said metanephric tissue into said recipient.

2. The method of claim 1 wherein said metanephric tissue is contacted with said growth factor-containing composition for less than 8 hours.

3. The method of claim 1 wherein said metanephric tissue is contacted with said growth factor-containing composition for less than 2 hours.

15. The method of claim 1, 4, 5, 8, 11, or 12 wherein said contacted metanephric tissue develops into a functional chimeric kidney in said recipient and wherein the glomeruli of said functional chimeric kidney are vascularized primarily by said recipient and are able to filter plasma.

4. A method for the treatment of metanephric tissue transplanted into a recipient comprising contacting said transplanted metanephric tissue with a growth factor-containing composition comprising vascular endothelial growth factor, wherein said growth factor-containing composition is administered to said transplanted metanephric tissue at the time a ureteroureterostomy is performed.

5. A method for the treatment of metanephric tissue comprising contacting said metanephric tissue, in vivo, with a growth factor-containing composition comprising vascular endothelial growth factor at the time of or after being said metanephric tissue is transplanted into said recipient.

6. The method of claim 5 wherein said growth factor-containing composition is administered to said metanephric tissue by an osmotic pump.

7. The method of claim 5 wherein said growth factor-containing composition is administered to said recipient in a manner such that said vascular endothelial growth factor is present in said recipient'"'"'s blood that circulates through said metanephric tissue.

8. A method for the treatment of metanephric tissue for transplantation into a recipient comprising:

a. contacting said metanephric tissue, in vitro, with a growth factor-containing composition comprising vitamin A; and

b. transplanting said metanephric tissue into said recipient.

9. The method of claim 8 wherein said metanephric tissue is contacted with said growth factor-containing composition for less than 8 hours.

10. The method of claim 8 wherein said metanephric tissue is contacted with said growth factor-containing composition for less than 2 hours.

11. A method for the treatment of metanephric tissue transplanted into a recipient comprising contacting said transplanted metanephric tissue with a growth factor-containing composition comprising vitamin A, wherein said growth factor-containing composition is administered to said transplanted metanephric tissue at the time a ureteroureterostomy is performed.

12. A method for the treatment of metanephric tissue comprising contacting said metanephric tissue, in vivo, with a growth factor-containing composition comprising vitamin A at the time of or after said metanephric tissue is transplanted into said recipient.

13. The method of claim 12 wherein said growth factor-containing composition is administered to said metanephric tissue by an osmotic pump.

14. The method of claim 12 wherein said growth factor-containing composition is administered to said recipient in a manner such that said vitamin A is present in said recipient'"'"'s blood that circulates through said metanephric tissue.